Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 8/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.58 |
| ▸ | MMP13 | P45452 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | BCL2 | P10415 | 1/20 | 0.48 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6264658 | 0.88 | NR1H4 (0.56) | NR1H4EPHX2MMP13HDAC6HDAC2 | |
| SCHEMBL6264656 | 0.83 | NR1H4 (0.56) | NR1H4EPHX2MMP13HDAC6HDAC2 | |
| SCHEMBL14044800 | 0.80 | HDAC2 (0.69) | NR1H4EPHX2HDAC6HDAC2HDAC8 | |
| SCHEMBL6271126 | 0.80 | MMP13 (0.54) | NR1H4EPHX2MMP13ALDH1A1 | |
| SCHEMBL6234382 | 0.79 | NR1H4 (0.56) | NR1H4EPHX2MMP13ALDH1A1PPARG | |
| SCHEMBL6234969 | 0.79 | NR1H4 (0.56) | NR1H4EPHX2MMP13ALDH1A1PPARG | |
| SCHEMBL6230534 | 0.78 | NR1H4 (0.55) | NR1H4EPHX2MMP13ALDH1A1GAA | |
| SCHEMBL6231446 | 0.78 | GAA (0.56) | NR1H4EPHX2MMP13ALDH1A1GAA | |
| SCHEMBL6237491 | 0.77 | EPHX2 (0.54) | NR1H4EPHX2HDAC6HDAC2HDAC8 | |
| SCHEMBL6271123 | 0.76 | KDM4E (0.54) | NR1H4EPHX2MMP13ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6849648-B2 | Phenylene alkyne matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-02-01 | — | — | US | disclosed |
| EP-1434585-A1 | ALKYNE MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20030144274-A1 | Alkyne matrix metalloproteinase inhibitors | BUNKER AMY MAE (US) | 2003-07-31 | — | — | US | disclosed |
| WO-2003032999-A1 | ALKYNE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144274-A1 | Alkyne matrix metalloproteinase inhibitors | MMP11, MMP13, MMP3 | NR1H4 2748/4885EPHX2 2781/4885MMP13 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.